MINING SERENDIPITY FROM DRUG REVIEWS USING SUPPORT VECTOR MACHINES
DOI:
https://doi.org/10.61841/smtsyy92Keywords:
Machine Learning, Sentiment Analysis, SerendipityAbstract
--Serendipity is all about the Positivity or Goodness. Sentiment analysis is that the process of determining whether an editorial is positive, negative or neutral. Analysing opinions allows data analysts on large companies to guage vox populi, conduct nuanced research, monitor brand and merchandise reputation and understand customer experience. The proposed model is trained and evaluated with a UCI ML dataset that describes drug use. If the patient's drug use effect might be computationally identified, it could help generate and validate drug repositioning hypotheses; Measures are often taken for that drug, both in production and in use. We investigate supervised machine learning models to extract positivity in drug use. Furthermore, the proposed model is compared with Naive Bayes. Finally, a machine learning model using Natural Language Processing techniques on drug usage review dataset is implemented to find the sentiment of drugs and results were presented.
Downloads
References
1. T. T. Ashburn and K. B. Thor, "Drug repositioning: identifying and developing new uses for existing drugs," Nature Review Drug Discovery, vol. 3, pp. 673-683, 2004.
2. J. T. Dudley, T. Deshpande, and A. J. Butte, "Exploiting drug–disease relationships for computational drug repositioning," Briefings in Bioinformatics, vol. 12, pp. 303-311, 2011.
3. L. Yao, Y. Zhang, Y. Li, P. Sanseau, and P. Agarwal, "Electronic health records: Implications for drug discovery," Drug Discovery Today, vol. 16, pp. 594-599, 2011.
4. C. Andronis, A. Sharma, V. Virvilis, S. Deftereos, and A. Persidis, "Literature mining, ontologies and information visualization for drug repurposing," Briefings in Bioinformatics, vol. 12, pp. 357- 368, 2011. TABLE VI. MODEL COMPLEXITY Variable CNN LSTM CLSTM CNN+FCN LSTM+FCN CLSTM+FCN Input dimensions 10,000 10,000 10,000 10,195 10,195 10,195 No. of
CNN filters 96 -- 384 768 -- 192 No. of FCN filters 128 -- 32 480 -- 480 No. of LSTM units -- 10
135 -- 35 120 No. of weights to train 345,889 8,665 380,561 1,532,833 51,297 446,561 IEEE
Transactions on NanoBioscience, Volume:18,Issue:3,Issue Date:July.2019
5. M. J. Keiser, V. Setola, J. J. Irwin, C. Laggner, A. Abbas, S. J. Hufeisen, et al., "Predicting new molecular targets for known drugs," Nature, vol. 462, pp. 175-181, 2009.
6. P. Sanseau, P. Agarwal, M. R. Barnes, T. Pastinen, J. B. Richards, L. R. Cardon, et al., "Use of genome-wide association studies for drug repositioning," Nature Biotechnology, vol. 30, pp. 317- 320, 2012.
7. A. Gottlieb, G. Y. Stein, E. Ruppin, and R. Sharan, "PREDICT: a method for inferring novel drug indications with application to personalized medicine," Molecular Systems Biology, vol. 7, p. 496, 2011.
8. J. D. Wren, R. Bekeredjian, J. A. Stewart, R. V. Shohet, and H. R. Garner, "Knowledge discovery by automated identification and ranking of implicit relationships," Bioinformatics, vol. 20, pp. 389- 398, 2004.
9. L. Yao, "In silico search for drug targets of natural compounds," Current pharmaceutical biotechnology, vol. 13, pp. 1632-1639, 2012.
10. H. Xu, M. C. Aldrich, Q. Chen, H. Liu, N. B. Peterson, Q. Dai, et al., "Validating drug repurposing signals using electronic health records: a case study of metformin associated with reduced cancer mortality," Journal of the American Medical Informatics Association, vol. 22, pp. 179-191, 2014
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
